GSK3B and graft versus host disease: While targeting NFAT also shows potent therapeutic efficacy against GVHD [40], its clinical efficacy and PP2B-NFAT or PP2B-GSK-3β activation in CD4+ lymphocytes of GVHD patients need to be validated.